GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B2260 WAY-100635 maleate saltSummary: 5-HT1A receptor antagonist -
B1368 Tizanidine HClSummary: α2-adrenergic receptor agonist -
B2259 VUF 10166Target: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist -
B2258 Tropisetron HydrochlorideTarget: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist -
B1367 SotalolSummary: Adrenergic receptor antagonist -
B2256 SB742457Summary: 5-HT6 receptor antagonist,highly selective and high affinity -
B1366 Naftopidil DiHClSummary: Selective 5-HT1A and α1-adrenergic receptor antagonist -
B2254 SB269970 HClSummary: 5-HT7 receptor antagonist,potent and selective -
B1365 Terazosin HClSummary: Selective α1-adrenoceptor antagonist -
B2253 PrucaloprideSummary: 5-HT4A and 5-HT4B receptor agonist
